An Overview of Botulinum Toxins: Past, Present, and Future

Clinics in Plastic Surgery

Volumn 38, Issue 3, 2011, Pages 409-426

  Cartee, Todd V ^a   Monheit, Gary D ^a  

^a TOTAL   (France)

Author keywords

Botox; Botulinum; Cosmetic; Dysport; Neurotoxin

Indexed keywords

ACETYLCHOLINE; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CALCITONIN GENE RELATED PEPTIDE; GLUTAMIC ACID; HUMAN SERUM ALBUMIN; LACTOSE; PLACEBO; RIMB; RT 001; SNARE PROTEIN; SODIUM CHLORIDE; SUBSTANCE P; SUCROSE; SYNAPTOBREVIN; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; SYNTAXIN; UNCLASSIFIED DRUG;

BLEPHAROSPASM; CERVICAL DYSTONIA; CHEMICAL COMPOSITION; CHOLINERGIC NERVE CELL; CHRONIC PAIN; CLOSTRIDIUM BOTULINUM; DRUG APPROVAL; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG INDICATION; DRUG MECHANISM; DRUG PACKAGING; ENDOCYTOSIS; ESTHETICS; HUMAN; HYPERHIDROSIS; INDIVIDUALIZATION; INHIBITION KINETICS; MEDICAL LITERATURE; OFF LABEL DRUG USE; PATIENT CARE; PATIENT SAFETY; PATIENT SATISFACTION; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL (TOPIC); PRESYNAPTIC NERVE; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; STORAGE TEMPERATURE; WRINKLE;

BLEPHAROPLASTY; BOTULINUM TOXINS; BOTULINUM TOXINS, TYPE A; ESTHETICS; HUMANS; NEUROMUSCULAR AGENTS; RHYTIDOPLASTY; SKIN AGING;

EID: 79961120309     PISSN: 00941298     EISSN: 15580504     Source Type: Journal    
DOI: 10.1016/j.cps.2011.03.010     Document Type: Review

References (61)

1. Data on file, Allergan, Inc. Safety analysis; from Allergan website. Available at: Accessed on October 1, 2010. http://www.botoxcosmetic.com/botox_physician_info/clinical_information.aspx.
2. Arnon S.S., Schechter R., Inglesby T.V., et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001, 285(8):1059-1070.
3. Henkel J.S., Jacobson M., Tepp W., et al. Catalytic properties of botulinum neurotoxin subtypes A3 and A4. Biochemistry 2009, 48(11):2522-2528.
4. Lacy D.B., Tepp W., Cohen A.C., et al. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol 1998, 5(10):898-902.
5. Koriazova L.K., Montal M. Translocation of botulinum neurotoxin light chain protease through the heavy chain channel. Nat Struct Biol 2003, 10(1):13-18.
6. Schiavo G., Matteoli M., Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol Rev 2000, 80(2):717-766.
7. Inoue K., Fujinaga Y., Watanabe T., et al. Molecular composition of Clostridium botulinum type A progenitor toxins. Infect Immun 1996, 64(5):1589-1594.
8. Lietzow M.A., Gielow E.T., Le D., et al. Subunit stoichiometry of the Clostridium botulinum type A neurotoxin complex determined using denaturing capillary electrophoresis. Protein J 2008, 27(7-8):420-425.
9. Cliff S.H., Judodihardjo H., Eltringham E. Different formulations of botulinum toxin type A have different migration characteristics: a double-blind, randomized study. J Cosmet Dermatol 2008, 7(1):50-54.
10. Pickett A. Dysport®: pharmacological properties and factors that influence toxin action. Toxicon 2009, 54(5):683-689.
11. Karl-Heinz E., Taylor H.V. Dissociation of the 900 kDa neurotoxin complex from C. botulinum under physiological conditions. Toxicon 2008, 51(Suppl 1):10.
12. Eisele K.-H., Fink K., Vey M., et al. Studies on the dissociation of botulinum neurotoxin type A complexes. Toxicon 2011, 57:555-565.
13. Botulinum toxin in clinical dermatology 2006, Taylor & Francis, Boca Raton (FL). A.V. Benedetto (Ed.).
14. Scott A.B. Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Ophthalmol Soc 1981, 79:734-770.
15. Carruthers J.D., Carruthers J.A. Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol 1992, 18(1):17-21.
16. Carruthers A., Carruthers J., Flynn T.C., et al. Dose-finding, safety, and tolerability study of Botulinum toxin type B for the treatment of hyperfunctional glabellar lines. Dermatol Surg 2007, 33:S60-S68.
17. Lowe N.J., Yamauchi P.S., Lask G.P., et al. Botulinum toxins types A and B for brow furrows: preliminary experiences with type B toxin dosing. J Cosmet Laser Ther 2002, 4(1):15-18.
18. Flynn T.C., Clark R.E. Botulinum toxin type B (MYOBLOC) versus Botulinum toxin type A (BOTOX) Frontalis Study: rate of onset and radius of diffusion. Dermatol Surg 2003, 29(5):519-522.
19. Alster T.S., Lupton J.R. Botulinum toxin type B for dynamic glabellar rhytides refractory to Botulinum toxin type A. Dermatol Surg 2003, 29(5):516-518.
20. Hambleton P., Pickett A.M. Potency equivalence of botulinum toxin preparations. J R Soc Med 1994, 87(11):719.
21. Karsai S., Raulin C. Current evidence on the unit equivalence of different Botulinum Neurotoxin A formulations and recommendations for clinical practice in dermatology. Dermatol Surg 2009, 35(1):1-8.
22. Sampaio C., Costa J., Ferreira J.J. Clinical comparability of marketed formulations of botulinum toxin. Mov Disord 2004, 19(Suppl 8):S129-S136.
23. Karsai S., Adrian R., Hammes S., et al. A randomized double-blind study of the effect of Botox and Dysport/Reloxin on forehead wrinkles and electromyographic activity. Arch Dermatol 2007, 143(11):1447-1449.
24. Lowe P., Patnaik R., Lowe N. Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: a double-blind, randomized study. J Am Acad Dermatol 2006, 55(6):975-980.
25. Trindade De Almeida A.R., Marques E., De Almeida J., et al. Pilot study comparing the diffusion of two formulations of Botulinum Toxin Type A in patients with forehead hyperhidrosis. Dermatol Surg 2007, 33:S37-S43.
26. Hexsel D., Dal'Forno T., Hexsel C., et al. A randomized pilot study comparing the action halos of two commercial preparations of Botulinum toxin type A. Dermatol Surg 2008, 34(1):52-59.
27. Sugawara Y., Fujinaga Y. The botulinum toxin complex meets E-cadherin on the way to its destination. Cell Adh Migr 2011, 5(1):34-36.
28. Sugawara Y., Matsumura T., Takegahara Y., et al. Botulinum hemagglutinin disrupts the intercellular epithelial barrier by directly binding E-cadherin. J Cell Biol 2010, 189(4):691-700.
29. Sattler G., Callander M.J., Grablowitz D., et al. Noninferiority of IncobotulinumtoxinA, free from complexing proteins, compared with another Botulinum toxin type A in the treatment of Glabellar Frown Lines. Dermatol Surg 2010, 36:2146-2154.
30. Brandt F., O'Connell C., Cazzaniga A., et al. Efficacy and safety evaluation of a novel botulinum toxin topical gel for the treatment of moderate to severe lateral canthal lines. Dermatol Surg 2010, 36:2111-2118.
31. Alam M., Dover J.S., Arndt K.A. Pain associated with injection of Botulinum A Exotoxin reconstituted using isotonic sodium chloride with and without preservative: a double-blind, randomized controlled trial. Arch Dermatol 2002, 138(4):510-514.
32. Carruthers J., Fagien S., Matarasso S.L., et al. Consensus recommendations on the use of botulinum toxin type a in facial aesthetics. Plast Reconstr Surg 2004, 114(6):1S-22S.
33. Carruthers A., Carruthers J., Cohen J. Dilution volume of botulinum toxin type A for the treatment of glabellar rhytides: does it matter?. Dermatol Surg 2007, 33(1 Spec No.):S97-S104.
34. Hexsel D.M., De Almeida A.T., Rutowitsch M., et al. Multicenter, double-blind study of the efficacy of injections with botulinum toxin type A reconstituted up to six consecutive weeks before application. Dermatol Surg 2003, 29(5):523-529. [discussion: 529].
35. Trindade De Almeida A.R., Kadunc B.V., Di Chiacchio N., et al. Foam during reconstitution does not affect the potency of botulinum toxin type A. Dermatol Surg 2003, 29(5):530-531. [discussion: 532].
36. Carruthers A., Carruthers J. Prospective, double-blind, randomized, parallel-group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatol Surg 2005, 31(10):1297-1303.
37. Kane M.A., Brandt F., Rohrich R.J., et al. Evaluation of variable-dose treatment with a new U.S. Botulinum Toxin Type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study. Plast Reconstr Surg 2009, 124(5):1619-1629.
38. Carruthers A., Carruthers J. Eyebrow height after botulinum toxin type a to the glabella. Dermatol Surg 2007, 33:S26-S31.
39. Maas C.S., Kim E.J. Temporal brow lift using botulinum toxin a: an update. Plast Reconstr Surg 2003, 112(5):109S-112S.
40. Carruthers A., Carruthers J., Monheit G.D., et al. Multicenter, randomized, parallel-group study of the safety and effectiveness of OnabotulinumtoxinA and Hyaluronic acid dermal fillers (24-mg/mL Smooth, Cohesive Gel) alone and in combination for lower facial rejuvenation. Dermatol Surg 2010, 36:2121-2134.
41. Brin M.F., Boodhoo T.I., Pogoda J.M., et al. Safety and tolerability of onabotulinumtoxinA in the treatment of facial lines: a meta-analysis of individual patient data from global clinical registration studies in 1678 participants. J Am Acad Dermatol 2009, 61(6):961-970. e1-11.
42. PubMed search string: (botulinum or Botox) AND (rash OR urticaria OR anaphylaxis OR allergy OR allergic).
43. Li M., Goldberger B.A., Hopkins C. Fatal case of BOTOX-related anaphylaxis?. J Forensic Sc 2005, 50(1):169-172.
44. Bowden J.B., Rapini R.P. Psoriasiform eruption from intramuscular botulinum A toxin. Cutis 1992, 50(6):415-416.
45. Brueggemann N., Doegnitz L., Harms L., et al. Skin reactions after intramuscular injection of Botulinum toxin A: a rare side effect. J Neurol Neurosurg Psychiatr 2008, 79(2):231-232.
46. LeWitt P.A., Trosch R.M. Idiosyncratic adverse reactions to intramuscular botulinum toxin type A injection. Mov Disord 1997, 12(6):1064-1067.
47. Mezaki T., Sakai R. Botulinum toxin and skin rash reaction. Mov Disord 2005, 20(6):770.
48. Cox N.H., Duffey P., Royle J. Fixed drug eruption caused by lactose in an injected botulinum toxin preparation. J Am Acad Dermatol 1999, 40(2):263-264.
49. Coté T.R., Mohan A.K., Polder J.A., et al. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol 2005, 53(3):407-415.
50. Ahbib S., Lachapelle J.M., Marot L. Ann Dermatol Venereol 2006, 133(1):43-45. [in French].
51. Mejia N.I., Vuong K.D., Jankovic J. Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord 2005, 20(5):592-597.
52. Kessler K.R., Skutta M., Benecke R. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group. J Neurol 1999, 246(4):265-274.
53. Lee S.-K. Antibody-induced failure of botulinum toxin type a therapy in a patient with masseteric hypertrophy. Dermatol Surg 2007, 33:S105-S110.
54. Dysport [package insert].
55. Alam M., Arndt K.A., Dover J.S. Severe, intractable headache after injection with botulinum a exotoxin: report of 5 cases. J Am Acad Dermatol 2002, 46(1):62-65.
56. Hevia O. Retrospective review of 500 patients treated with abobotulinumtoxinA. J Drugs Dermatol 2010, 9(9):1081-1084.
57. Wortzman M.S., Pickett A. The science and manufacturing behind botulinum neurotoxin type A-ABO in clinical use. Aesthetic Surg J 2009, 29(Suppl 6):S34-S42.
58. Pickett A., Perrow K. Formulation composition of botulinum toxins in clinical use. J Drugs Dermatol 2010, 9(9):1085-1091.
59. BOTOX cosmetic [package insert].
60. Xeomin cosmetic [package insert].
61. Carruthers A., Carruthers J. Botulinum toxin products overview. Skin Therapy Lett 2008, 13(6):1-4.